DE60040755D1 - Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) - Google Patents
Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv)Info
- Publication number
- DE60040755D1 DE60040755D1 DE60040755T DE60040755T DE60040755D1 DE 60040755 D1 DE60040755 D1 DE 60040755D1 DE 60040755 T DE60040755 T DE 60040755T DE 60040755 T DE60040755 T DE 60040755T DE 60040755 D1 DE60040755 D1 DE 60040755D1
- Authority
- DE
- Germany
- Prior art keywords
- hcv
- hepatitis
- virus
- antibodies
- recognition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16823499P | 1999-12-01 | 1999-12-01 | |
US18505500P | 2000-02-25 | 2000-02-25 | |
PCT/US2000/042541 WO2001047551A2 (en) | 1999-12-01 | 2000-12-01 | Eliciting antibodies specific for hepatitis c virus (hcv) |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60040755D1 true DE60040755D1 (de) | 2008-12-18 |
Family
ID=26863907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040755T Expired - Lifetime DE60040755D1 (de) | 1999-12-01 | 2000-12-01 | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
Country Status (12)
Country | Link |
---|---|
US (3) | US7329408B2 (de) |
EP (1) | EP1233782B1 (de) |
JP (1) | JP2004500366A (de) |
AT (1) | ATE413190T1 (de) |
AU (1) | AU5442501A (de) |
CA (1) | CA2393251C (de) |
CY (1) | CY1108734T1 (de) |
DE (1) | DE60040755D1 (de) |
DK (1) | DK1233782T3 (de) |
ES (1) | ES2319727T3 (de) |
PT (1) | PT1233782E (de) |
WO (1) | WO2001047551A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1232267B1 (de) * | 1999-10-27 | 2013-03-20 | Novartis Vaccines and Diagnostics, Inc. | Aktivierung von hcv-spezifischen t-zellen |
ATE413190T1 (de) * | 1999-12-01 | 2008-11-15 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
AUPQ797700A0 (en) * | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
JP4370161B2 (ja) * | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Hcve1e2ワクチン組成物 |
CU23244A1 (es) * | 2001-07-16 | 2007-10-17 | Ct Ingenieria Genetica Biotech | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
CA2461380C (en) | 2001-10-11 | 2011-03-22 | Merck & Co., Inc. | Hepatitis c virus vaccine |
WO2004060396A2 (en) | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
US20050191358A1 (en) * | 2003-01-14 | 2005-09-01 | Derek O' Hagan | Microparticles with adsorbed polynucleotide-containing species |
WO2004071414A2 (en) * | 2003-02-05 | 2004-08-26 | Genzyme Corporation | Therapeutic anti-hcv (al9) compounds |
EP1610757A4 (de) * | 2003-04-10 | 2007-05-30 | Transform Pharmaceuticals Inc | Profilierung von konformationsvarianten, antikörper-zusammensetzungen und anwendungsverfahren dafür |
NZ543343A (en) * | 2003-04-25 | 2008-03-28 | Novartis Vaccines & Diagnostic | Compositions comprising cationic microparticles and HCV E1E2 DNA and methods of use thereof |
ES2596553T3 (es) * | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido |
NZ551319A (en) * | 2004-05-17 | 2010-07-30 | Novartis Vaccines & Diagnostic | Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same |
US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
DE602005026545D1 (de) * | 2004-08-24 | 2011-04-07 | Tokyo Metropolitan Org Med Res | Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz |
CA2587712C (en) * | 2004-11-18 | 2013-02-12 | National University Of Corporation Hiroshima University | Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant |
ES2551113T3 (es) * | 2006-01-04 | 2015-11-16 | Glaxosmithkline Biologicals S.A. | Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC |
US20100291545A1 (en) | 2007-07-25 | 2010-11-18 | Takaji Wakita | Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof |
JP5756757B2 (ja) | 2009-10-30 | 2015-07-29 | 東レ株式会社 | C型肝炎ウイルス(hcv)に対して感染阻害活性を有する抗体及びその用途 |
JP5897024B2 (ja) * | 2010-11-26 | 2016-03-30 | ザ マクファーレーン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッドThe Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 組成物および方法 |
CA2922698C (en) | 2013-08-29 | 2023-01-03 | City Of Hope | Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids |
WO2017048807A1 (en) | 2015-09-17 | 2017-03-23 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration or moisturization |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE318216T1 (de) * | 1987-11-18 | 1990-06-13 | Chiron Corp., Emeryville, Calif., Us | Nanbv-diagnostika und vakzine. |
US5350671A (en) | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
US5471330A (en) | 1993-07-29 | 1995-11-28 | Honeywell Inc. | Polysilicon pixel electrode |
CA2195312A1 (en) | 1994-07-29 | 1996-02-15 | Mark Selby | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
AU3241095A (en) | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
GB9416671D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
JP2000500744A (ja) * | 1995-11-09 | 2000-01-25 | マイクロバイオロジカル リサーチ オーソリティー | ワクチン接種および遺伝子治療のためのマイクロカプセル化dna |
US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
WO1998050556A2 (en) | 1997-05-06 | 1998-11-12 | Chiron Corporation | Intracellular production of hepatitis c e1 and e2 truncated polypeptides |
JP2001512662A (ja) * | 1997-07-18 | 2001-08-28 | コノート ラボラトリーズ リミテッド | 呼吸器合胞体ウイルスのgタンパク質をコードする核酸ワクチン |
PT1042001E (pt) * | 1997-12-16 | 2002-09-30 | Chiron Corp | Uso de microparticulas combinadas com emulsoes submicronicas oleo-em-agua |
EP1232267B1 (de) | 1999-10-27 | 2013-03-20 | Novartis Vaccines and Diagnostics, Inc. | Aktivierung von hcv-spezifischen t-zellen |
ATE413190T1 (de) * | 1999-12-01 | 2008-11-15 | Novartis Vaccines & Diagnostic | Hervorrufen von antikörpern spezifisch für hepatitis c virus (hcv) |
-
2000
- 2000-12-01 AT AT00993586T patent/ATE413190T1/de active
- 2000-12-01 US US09/728,423 patent/US7329408B2/en not_active Expired - Lifetime
- 2000-12-01 WO PCT/US2000/042541 patent/WO2001047551A2/en active Application Filing
- 2000-12-01 PT PT00993586T patent/PT1233782E/pt unknown
- 2000-12-01 ES ES00993586T patent/ES2319727T3/es not_active Expired - Lifetime
- 2000-12-01 EP EP00993586A patent/EP1233782B1/de not_active Expired - Lifetime
- 2000-12-01 CA CA2393251A patent/CA2393251C/en not_active Expired - Fee Related
- 2000-12-01 AU AU54425/01A patent/AU5442501A/en not_active Abandoned
- 2000-12-01 JP JP2001548141A patent/JP2004500366A/ja active Pending
- 2000-12-01 DE DE60040755T patent/DE60040755D1/de not_active Expired - Lifetime
- 2000-12-01 DK DK00993586T patent/DK1233782T3/da active
-
2007
- 2007-12-13 US US12/001,920 patent/US20080095800A1/en not_active Abandoned
-
2009
- 2009-01-27 CY CY20091100101T patent/CY1108734T1/el unknown
-
2010
- 2010-08-30 US US12/871,035 patent/US20110159039A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DK1233782T3 (da) | 2009-02-09 |
WO2001047551A2 (en) | 2001-07-05 |
WO2001047551A3 (en) | 2002-03-14 |
EP1233782B1 (de) | 2008-11-05 |
CA2393251C (en) | 2012-01-31 |
CA2393251A1 (en) | 2001-07-05 |
ES2319727T3 (es) | 2009-05-12 |
AU5442501A (en) | 2001-07-09 |
US20080095800A1 (en) | 2008-04-24 |
EP1233782A2 (de) | 2002-08-28 |
ATE413190T1 (de) | 2008-11-15 |
JP2004500366A (ja) | 2004-01-08 |
PT1233782E (pt) | 2009-02-13 |
US7329408B2 (en) | 2008-02-12 |
CY1108734T1 (el) | 2014-04-09 |
US20110159039A1 (en) | 2011-06-30 |
US20020002272A1 (en) | 2002-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108734T1 (el) | Αναπτυξη αντισωματων ειδικων για hcv | |
WO2002061576A3 (en) | System, method and article of manufacture for interface constructs in a programming language capable of programming hardware architectures | |
DK1294893T3 (da) | Modifikation af hepatitis B-kerneantigen | |
ATE109795T1 (de) | Htlv-iii umhüllende peptiden. | |
DE3784484T2 (de) | Hepatitis nanb-viraler stoff, antigen und immunologisches reagenz. | |
ATE411387T1 (de) | Rabiesvirus-spezifische neutralisierende humane monoklonale antikörper und nukleinsäure und relatierte verfahren | |
DK101888D0 (da) | Immunmodulerende midler og anvendelse af disse | |
FI935217A (fi) | Basisk dissocieringsanalys | |
EP0769696A3 (de) | Antikörper und Proteine zur Bestimmung einer viralen Infektion der Weinrebe | |
NO973875D0 (no) | Fremgangsmåte for simulering av en immunrespons | |
Atanasiu et al. | Rapid immunoenzymatic technique for titration of rabies antibodies IgG and IgM results | |
DE60324003D1 (en) | Hcv-test | |
DE69334328D1 (de) | Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits | |
FI950248A0 (fi) | Rokotteita monisoluisia loisia vastaan | |
DK1417233T3 (da) | Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf | |
DK0476059T3 (da) | Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger | |
DK0556320T3 (da) | Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf | |
WO2001093804A3 (en) | Hepatitis c virus conjugates | |
EP1394548A3 (de) | Methode zur serologischen Typisierung mittels typspezifischer Antigene | |
ES2013665A6 (es) | Procedimiento para preparar un anticuerpo monoclonal humano y metodo de uso. | |
DK230090A (da) | Peptider | |
DE68918440D1 (de) | Verfahren zur transformation von menschlichen b-lymphocyten. | |
ATE338061T1 (de) | Synthetische peptide die immunoreaktivität gegen den virus von hepatitis a zeigen | |
DE69331796T2 (de) | Kernantigenprotein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Satz von Reagenzen | |
WO2003014728A1 (fr) | Medicaments contre l'hepatite c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |